A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial
Sube Banerjee(University of Nottingham), Naji Tabet(Brighton and Sussex Medical School), John T. O’Brien(North Tyneside General Hospital), Alistair Burns(University of Manchester), Nicolas Farina(Brighton and Sussex Medical School), Ramin Nilforooshan(University of Surrey), Lee Shepstone(University of East Anglia), Clive Ballard(University of Exeter), Alan Thomas(Cleveland Clinic), Catherine Henderson(London School of Economics and Political Science), Julia Fountain(Sussex Partnership NHS Foundation Trust), Paul T. Francis(King's College London), Peter Bentham(Queen Elizabeth Hospital Birmingham), Juliet High(National Cancer Institute), Shirley Nurock(Alzheimer's Society), Tanya Telling(University of Sussex), Gill Livingston(North East London NHS Foundation Trust), Ann Marie Swart(University of East Anglia), Chris Fox(University of California, Irvine), Annabel Price(Cambridgeshire and Peterborough NHS Foundation Trust), Susan Stirling(University of East Anglia), Iracema Leroi(Trinity College Dublin), Martín Knapp(London School of Economics and Political Science)
Cited by 8
Related Papers
Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science
|The Lancet Psychiatry|2020|6k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
|The Lancet|2024|2.8k
Cost of disorders of the brain in Europe 2010
|European Neuropsychopharmacology|2011|1.7k